Breaking Finance News

Adverum Biotechnologies (NDAQ:ADVM) target raised to $6.00, reported today by Raymond James

Showing a price of $3.99, Adverum Biotechnologies (NDAQ:ADVM) traded 3.47% higher on the day. With the last close up 38.86% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the same time period. ADVM has recorded a 50-day moving average of $2.59 and a 200-day moving average of $2.68. 326,691 shares of ADVM traded hands, up from an average trading volume of 280,567

Adverum Biotechnologies (NDAQ:ADVM) had its stock price target increased to $6.00 by Raymond James in an issued report issued 10/12/2017. The upped price target implies a possible upside of 0.50% based on the company's most recent stock price close.

See Chart Below

Adverum Biotechnologies (NDAQ:ADVM)

Adverum Biotechnologies has a 52 week low of $2.40 and a 52 week high of $4.17 The company’s market cap is currently $0.

In addition to Raymond James reporting its target price, a total of 3 firms have reported on the company. The average stock price target is $9.50 with 1 broker rating the stock a strong buy, 2 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Adverum Biotechnologies (NDAQ:ADVM)

Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics. It focuses on diseases with unmet medical need, including ophthalmic diseases, such as wet age-related macular degeneration (AMD), as well as rare genetic diseases. The Company's product candidates include AVA-101 and AVA-201 for treatment of Wet AMD; AVA-322 and AVA-323 for the treatment of Color Vision Deficiency, and AVA-311 for the treatment of Juvenile X-linked Retinoschisis. It has generated human proof-of-concept data for AVA-101 in a Phase I trial with over eight wet AMD subjects conducted at Lions Eye Institute (LEI) in Australia. It is developing AVA-322 and AVA-323 for the treatment of color vision deficiency (CVD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.